ХИМИОИНДУЦИРОВАННЫЕ ПОЛИНЕЙРОПАТИИ ПРИ ОНКОПАТОЛОГИИ ЯИЧНИКОВ: ПАТОГЕНЕЗ И ВОЗМОЖНОСТИ ТЕРАПИИ
Ключевые слова:
химиоиндуцированная полинейропатия, химиотерапия, рак яичников, патогенез, нейротоксичностьАннотация
Химиоиндуцированная полинейропатия (ХИП)– это один из часто встречающихся побочных эффектов химиотерапии. Более того, комбинация препаратов использующихся для лечения онкогинекологических заболеваний вызывает полинейропатию у 97% больных. В атипичных клетках эти препараты способствуют гибели клеток за счет прерывания клеточного митоза. Однако они также действуют на клетки периферической и центральной нервной системы. В этом обзоре подробно описываются патомеханизмы действия различных препаратов , используемых при химиотерапии рака яичников на периферическую нервную систему. Кроме того проведен анализ публикаций , связанных с ХИП с 2010 по 2022 год, целью которого было получение полной информации о существующих методах терапии данной патологии.
Библиографические ссылки
Aghili M, Zare M, Mousavi N, Ghalehtaki R, Sotoudeh S, Kalaghchi B, et al.. Efficacy of Gabapentin for the Prevention of Paclitaxel Induced Peripheral Neuropathy: A Randomized Placebo Controlled Clinical Trial. Breast J (2019) 25(2):226–31.
Anoushirvani AA, Poorsaadat L, Aghabozorgi R, Kasravi M. Comparison of the Effects of Omega 3 and Vitamin E on Palcitaxel-Induced Peripheral Neuropathy. Open Access Macedonian J Med Sci (2018) 62018:1857–61.
Argyriou AA, Bruna J, Park SB, Cavaletti G. Emerging pharmacological strategies for the management of chemotherapy-induced peripheral neurotoxicity (CIPN), based on novel CIPN mechanisms. Expert Rev Neurother. 2020;20:1005–1016.
Bakitas MA. Background noise: the experience of chemotherapy-induced peripheral neuropathy. Nurs Res. 2007;56:323–331.
Banach M, Juranek JK, Zygulska AL. Chemotherapy-induced neuropathies-a growing problem for patients and health care providers. Brain Behav. 2017;7
Bernhardson BM, Tishelman C, Rutqvist LE. Chemosensory changes experienced by patients undergoing cancer chemotherapy: a qualitative interview study. J Pain Symptom Manage. 2007;34:403–412.
Beijers AJM, Bonhof CS, Mols F, Ophorst J, de Vos-Geelen J, Jacobs EMG, et al.. Multicenter Randomized Controlled Trial to Evaluate the Efficacy and Tolerability of Frozen Gloves for the Prevention of Chemotherapy-Induced Peripheral Neuropathy. Ann Oncol (2020) 31(1):131–6.
Brewer JR, Morrison G, Dolan ME, Fleming GF. Chemotherapy-induced peripheral neuropathy: Current status and progress. Gynecol Oncol. 2016;140:176–183.
Cioroiu C, Weimer LH. Update on chemotherapy-induced peripheral neuropathy. Curr Neurol Neurosci Rep. 2017; 17(6):47.
Cavaletti G, Marmiroli P. Pharmacotherapy options for managing chemotherapy-induced peripheral neurotoxicity. Expert Opin Pharmacother. 2018;19:113–121.
De Iuliis F, Taglieri L, Salerno G, Lanza R, Scarpa S. Taxane induced neuropathy in patients affected by breast cancer: Literature review. Crit Rev Oncol Hematol. 2015;96:34–45.
Edwards HL, Mulvey MR, Bennett MI (2019) Cancer-related neuropathic pain. Cancers (Basel) 11(3) .
Ezendam NP, Pijlman B, Bhugwandass C, Pruijt JF, Mols F, Vos MC, Pijnenborg JM, van de Poll-Franse LV. Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry. Gynecol Oncol. 2014;135:510–517.
Ghoreishi Z, Esfahani A, Djazayeri A, Djalali M, Golestan B, Ayromlou H, et al.. Omega-3 Fatty Acids are Protective Against Paclitaxel-Induced Peripheral Neuropathy: A Randomized Double-Blind Placebo Controlled Trial. BMC Cancer (2012) 12:355.
Glare PA, Davies PS, Finlay E, Gulati A, Lemanne D, Moryl N, Oeffinger KC, Paice JA, Stubblefield MD, Syrjala KL. Pain in cancer survivors. J Clin Oncol. 2014;32:1739–1747.
Hausheer FH, Schilsky RL, Bain S, Berghorn EJ, Lieberman F. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Semin Oncol. 2006; 33(1):15–49.
Hilpert F, Stahle A, Tome O, Burges A, Rossner D, Spathe K, et al.. Neuroprotection With Amifostine in the First-Line Treatment of Advanced Ovarian Cancer With Carboplatin/Paclitaxel-Based Chemotherapy–a Double-Blind, Placebo-Controlled, Randomized Phase II Study From the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Care Cancer (2005) 13(10):797–805.
Hershman DL, Unger JM, Crew KD, Till C, Greenlee H, Minasian LM, et al.. Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715). J Natl Cancer Inst (2018) 110(6):669–76.
Herdsman DL, Unger JM, Crew KD, Till C, Greenlee H, Minasian LM, et al.. Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715). J Natl Cancer Inst (2018) 110(6):669–76.
Kanbayashi Y, Sakaguchi K, Ishikawa T, Ouchi Y, Nakatsukasa K, Tabuchi Y, et al.. Comparison of the Efficacy of Cryotherapy and Compression Therapy for Preventing Nanoparticle Albumin-Bound Paclitaxel-Induced Peripheral Neuropathy: A Prospective Self-Controlled Trial. Breast (2020) 49:219–24.
Khalefa HG, Shawki MA, Aboelhassan R, El Wakeel LM. Evaluation of the Effect of N-Acetylcysteine on the Prevention and Amelioration of Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer Patients: A Randomized Controlled Study. Breast Cancer Res Treat (2020) 183(1):117–25.
Kotani H, Terada M, Mori M, Horisawa N, Sugino K, Kataoka A, et al.. Compression Therapy Using Surgical Gloves Does Not Prevent Paclitaxel-Induced Peripheral Neuropathy: Results From a Double-Blind Phase 2 Trial. BMC Cancer (2021) 21(1):548.
Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol. 2020;38:3325–3348.
Leal AD, Qin R, Atherton PJ, Haluska P, Behrens RJ, Tiber C, et al.. NCCTG N08CA (Alliance): The Use of Glutathione for Prevention of Paclitaxel/Carboplatin Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind Placebo-Controlled Study. Cancer (2014) 120(12):1890–7.
Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L. Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer. 2014;22:2261–2269.
Ruddy KJ, Le-Rademacher J, Lacouture ME, Wilkinson M, Onitilo AA, Vander Woude AC, et al.. Randomized Controlled Trial of Cryotherapy to Prevent Paclitaxel-Induced Peripheral Neuropathy (RU221511I); an ACCRU Trial. Breast (2019) 48:89–97.
Scholz J, Finnerup NB, Attal N, Aziz Q. Classification Committee of the Neuropathic Pain Special Interest Group. The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain. 2019;160(1):53–59.
Staff NP, Grisold A, Grisold W, Windebank AJ. Chemotherapy-induced peripheral neuropathy: A current review. Ann Neurol. 2017;81:772–781.
Shinde SS, Seisler D, Soori G, Atherton PJ, Pachman DR, Lafky J, et al.. Can Pregabalin Prevent Paclitaxel-Associated Neuropathy?–An ACCRU Pilot Trial. Support Care Cancer (2016) 24(2):547–53.
Scripture CD, Figg WD, Sparreboom A. Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Curr Neuropharmacol. 2006;4:165–172.
Tofthagen C. Surviving chemotherapy for colon cancer and living with the consequences. J Palliat Med. 2010;13:1389–1391.
Tsuyuki S, Senda N, Kanng Y, Yamaguchi A, Yoshibayashi H, Kikawa Y, et al.. Evaluation of the Effect of Compression Therapy Using Surgical Gloves on Nanoparticle Albumin-Bound Paclitaxel-Induced Peripheral Neuropathy: A Phase II Multicenter Study by the Kamigata Breast Cancer Study Group. Breast Cancer Res Treat (2016) 160(1):61–7.
Wu S, Bai X, Guo C, Huang Z, Ouyang H, Huang J, Zeng W. Ganglioside-monosialic acid (GM1) for prevention of chemotherapy-induced peripheral neuropathy: a meta-analysis with trial sequential analysis. BMC Cancer. 2021 Nov 2;21(1):1173.
Zis P, Varrassi G, Vadalouka A, Paladini A. Psychological Aspects and Quality of Life in Chronic Pain. Pain Res Manag. 2019;2019:8346161.
